Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.59 |
| ▸ | USP7 | Q93009 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | CCR6 | P51684 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13393866 | 0.92 | CYP3A4 (0.73) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL82945 | 0.92 | NOS2 (0.73) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12136833 | 0.92 | NOS2 (0.73) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12447479 | 0.92 | CYP3A4 (0.73) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL82937 | 0.92 | CYP3A4 (0.73) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10175977 | 0.91 | NOS2 (0.62) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL84160 | 0.91 | NOS2 (0.63) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10175989 | 0.90 | NOS2 (0.60) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL12200341 | 0.90 | NFE2L2 (0.74) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL83431 | 0.90 | MBOAT4 (0.62) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9889143-B2 | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9757359-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170165278-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-9512094-B2 | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150152071-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20140328809-A1 | METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2014-11-06 | — | — | US | disclosed |
| US-20140088163-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8455544-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | Reata Pharmaecuticals, Inc. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120220652-A1 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease | REATA PHARMACEUTICALS, INC. | 2012-08-30 | — | — | US | disclosed |
| US-8129429-B2 | Synthetic triterpenoids and methods of use in the treatment of disease | REATA PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090060873-A1 | Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris | REATA PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152071-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | CYP46A1, CYP11B1, ALOX12 | NOS2 534/4885KEAP1 170/4885CYP3A4 105/4885 |
| US-20090326063-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885KEAP1 444/4885CYP3A4 752/4885 |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885KEAP1 444/4885CYP3A4 752/4885 |
| US-20090048205-A1 | COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE | RABGGTB, BAD, PGGT1B | NOS2 3154/4885KEAP1 1567/4885CYP3A4 1771/4885 |
| US-20090060873-A1 | Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris | GAP43, BDNF, PMP22 | NOS2 2334/4885KEAP1 261/4885CYP3A4 1761/4885 |
| US-20120220652-A1 | Synthetic Triterpenoids and Methods of Use in the Treatment of Disease | LIPG, CYP27A1, CYP11B1 | NOS2 378/4885KEAP1 444/4885CYP3A4 752/4885 |
| US-20170165278-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | CYP46A1, CYP11B1, ALOX12 | NOS2 534/4885KEAP1 170/4885CYP3A4 105/4885 |
| US-20140328809-A1 | METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS | BMP2, BMP4, EBP | NOS2 876/4885KEAP1 702/4885CYP3A4 4475/4885 |
| US-20140088163-A1 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | CYP46A1, CYP11B1, ALOX12 | NOS2 534/4885KEAP1 170/4885CYP3A4 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.